Vistagen Therapeutics Reports Financial Results and Operational Updates for Fiscal Year Ended March 31, 2026

Vistagen Therapeutics Reports Financial and Operational Updates for Fiscal Year Ended March 31, 2026

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, has reported its financial and operational results for the fiscal year ended March 31, 2026. The company experienced an increase in sublicense and other revenue, which rose to $1.3 million from $0.5 million in the prior fiscal year. This increase is primarily attributed to the timing of revenue recognition under the AffaMed Agreement. Research and development expenses for the fiscal year totaled $55.0 million, an increase of $15.6 million, or 39.6%, compared to $39.4 million in the prior year. This rise in R&D spending was largely driven by increased clinical trial activity for fasedienol, the company's most advanced product candidate. General and administrative expenses also saw an increase, reaching $18.4 million for the fiscal year, up from $17.1 million in the previous year, primarily due to higher corporate legal expenses and salaries.

The company's net loss for the fiscal year ended March 31, 2026, was $69.7 million, an increase from the $51.4 million net loss reported for the fiscal year ended March 31, 2025. This widening net loss reflects the increased research and development expenditures. As of March 31, 2026, Vistagen held $45.4 million in cash, cash equivalents, and marketable securities, a decrease from $80.5 million at the end of the prior fiscal year. This reduction in cash reserves is primarily due to the use of cash to fund ongoing operations and clinical development programs. The company has concluded that substantial doubt exists about its ability to continue as a going concern for a period of at least twelve months from the issuance date of its consolidated financial statements.

In terms of strategic and operational developments, Vistagen continues to advance its pipeline of intranasal pherine product candidates. The company's PALISADE Program, investigating fasedienol for the acute treatment of social anxiety disorder (SAD), remains a primary focus. While PALISADE-2 achieved its primary efficacy endpoint, PALISADE-1 and PALISADE-3 did not meet their primary endpoints. Topline results from the randomized portion of PALISADE-4 are anticipated in the second quarter of calendar 2026. The company also reported positive results from exploratory Phase 2A clinical trials for itruvone (major depressive disorder) and refisolone (vasomotor symptoms due to menopause and premenstrual dysphoric disorder), as well as pilot studies for PH15 (psychomotor impairment due to mental fatigue) and PH284 (cancer cachexia). Vistagen received a 'Study May Proceed' letter from the FDA for refisolone in April 2026, enabling further Phase 2 clinical development in the U.S.

In March 2026, Vistagen implemented a workforce reduction of approximately 20% to manage cash disciplinedly and prioritize the execution of ongoing clinical studies for fasedienol. The company continues to rely on third-party contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) for various operational aspects. Vistagen has also entered into a license and collaboration agreement with AffaMed Therapeutics, Inc. for fasedienol in Greater China and other Asian territories, and an exclusive negotiation agreement with Fuji Pharma Co., Ltd. for refisolone in Japan.

Looking ahead, Vistagen anticipates continued substantial investment in research and development to advance its product candidates through clinical trials and toward potential regulatory approval. The company's future capital requirements will depend on various factors, including the progress and outcomes of its clinical trials, regulatory feedback, and the costs associated with manufacturing and potential commercialization. Vistagen plans to seek substantial additional financing through equity or debt offerings, or strategic collaborations, to fund its operations and development programs. The company's ability to secure future funding and achieve regulatory approval and commercial success for its product candidates remains subject to significant risks and uncertainties.